Thijs Hendrikx - Concepedia

Author

Thijs Hendrikx

Pfizer (United States)ORCID

Also Known As

T Hendrikx, T. Hendrikx, T. K. Hendrikx, T.K. Hendrikx, Thijs Hendrikx, Thijs K. Hendrikx, Thijs L. Hendrikx

Publications

2.7K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)Erasmus MC Swedish Medical Center The University of Queensland Galapagos (Netherlands)

About

Thijs Hendrikx is an author at Pfizer (United States) specializing in medicine, rheumatoid arthritis, and autoimmune disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	295
2	Immunology	2	2	33
3	Orthopaedics	2	2	262
4	Nephrology	1	1	13
5	Pharmacology	1	1	20

Thijs Hendrikx

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis Philip J. Mease, Stephen Hall, Oliver FitzGerald, New England Journal of Medicine	2017	536
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors Dafna D. Gladman, William F. C. Rigby, Valderílio Feijó Azevedo, New England Journal of Medicine	2017	494
Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study Désirée van der Heijde, Atul Deodhar, James Cheng‐Chung Wei, Annals of the Rheumatic Diseases	2017	361
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial Désirée van der Heijde, Xenofon Baraliakos, Lianne S. Gensler, The Lancet Rheumatoid DisorderRheumatologyAutoimmune DiseaseSpondyloarthritisOsteoarthritis	2018	251
End-stage renal failure and regulatory activities of CD4+CD25bright+FoxP3+ T-cells Thijs Hendrikx, Evelien A. F. J. van Gurp, Wendy M. Mol, Nephrology Dialysis Transplantation	2009	105
Impact of Immunosuppressive Drugs on CD4+CD25+FOXP3+ Regulatory T Cells Ahmet Demirkıran, Thijs Hendrikx, Carla C. Baan, Transplantation	2008	102
Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs Christina Charles‐Schoeman, Gerd R Burmester, Peter Nash, Annals of the Rheumatic Diseases	2015	77
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs Vibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, RMD Open	2019	70
Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond Vibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, RMD Open	2019	65
The effect of rabbit anti-thymocyte globulin induction therapy on regulatory T cells in kidney transplant patients Varsha D. K. D. Sewgobind, Marcia M. L. Kho, Luc J. W. van der Laan, Nephrology Dialysis Transplantation	2009	56

Page 1